Projects per year
Fingerprint Dive into the research topics where Sumithra J Mandrekar is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 19 Similar Profiles
Non-Small Cell Lung Carcinoma
Medicine & Life Sciences
Clinical Trials
Medicine & Life Sciences
Neoplasms
Medicine & Life Sciences
Lung Neoplasms
Medicine & Life Sciences
Therapeutics
Medicine & Life Sciences
Biomarkers
Medicine & Life Sciences
Survival
Medicine & Life Sciences
Disease-Free Survival
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects 2014 2018
Validation of New Tumor Measurement-based Phase II Clinical Trial Endpoints
Project: Research project
Statistics and Data Center for the Alliance for Clinical Trials in Oncology
Mandrekar, S. J. & Sargent, D. J.
Project: Research project
Methodology for development, validation, and use of novel endpoints in oncology
Sargent, D. J. & Mandrekar, S. J.
2/1/14 → 1/31/18
Project: Research project
Biomarkers
Clinical Trials
Therapeutics
Research
Population
Research Output 2003 2019
Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia
Ruppert, A. S., Yin, J., Davidian, M., Tsiatis, A. A., Byrd, J. C., Woyach, J. A. & Mandrekar, S. J., Apr 1 2019, In : Annals of oncology : official journal of the European Society for Medical Oncology. 30, 4, p. 542-550 9 p.Research output: Contribution to journal › Article
Open Access
B-Cell Chronic Lymphocytic Leukemia
Maintenance
PCI 32765
Residual Neoplasm
Sample Size
Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614)
Yin, J., Laplant, B., Uy, G. L., Marcucci, G., Blum, W., Larson, R. A., Stone, R. M. & Mandrekar, S. J., Jun 11 2019, In : Blood Advances. 3, 11, p. 1714-1721 8 p.Research output: Contribution to journal › Article
Open Access
Acute Myeloid Leukemia
Disease-Free Survival
Cell Transplantation
Random Allocation
Endpoint Determination
3
Citations
(Scopus)
gBOIN: a unified model-assisted phase I trial design accounting for toxicity grades, and binary or continuous end points
Mu, R., Yuan, Y., Xu, J., Mandrekar, S. J. & Yin, J., Feb 1 2019, In : Journal of the Royal Statistical Society. Series C: Applied Statistics. 68, 2, p. 289-308 20 p.Research output: Contribution to journal › Article
Phase I Trial
End point
Toxicity
Binary
Dose
Ibrutinib Regimens in Older Patients with Untreated CLL. Reply
Woyach, J. A., Ruppert, A. S. & Mandrekar, S. J., Apr 25 2019, In : The New England journal of medicine. 380, 17, p. 1680-1681 2 p.Research output: Contribution to journal › Letter
Pyrazoles
Pyrimidines
PCI 32765
Improving attribution of adverse events in oncology clinical trials
George, G. C., Barata, P. C., Campbell, A., Chen, A., Cortes, J. E., Hyman, D. M., Jones, L., Karagiannis, T., Klaar, S., Le-Rademacher, J., LoRusso, P., Mandrekar, S. J., Merino, D. M., Minasian, L. M., Mitchell, S. A., Montez, S., O'Connor, D. J., Pettit, S., Silk, E., Sloan, J. A. & 6 others, , Jun 1 2019, In : Cancer Treatment Reviews. 76, p. 33-40 8 p.Research output: Contribution to journal › Review article
Clinical Trials
Research Personnel
Causality
Translational Medical Research
Contracts